Journal: Oncotarget

Article Title: IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model

doi: 10.18632/oncotarget.19786

Figure Lengend Snippet: (A) NSCLC xenografts were treated with recombinant human IL-33 protein or the control and detected for tumor growth at the indicated time. (B, C) NSCLC xenografts were treated with recombinant human IL-33 protein plus IL-33 neutralizing antibody (B) or ST2 neutralizing antibody (C). (D, E) NSCLC xenografts were treated with IL-33 neutralizing antibody (D) or ST2 neutralizing antibody (E) and analyzed for tumor growth. Shown are mean±SEM from 6 independent experiments.

Article Snippet: Recombinant human IL-33 protein, human M-CSF protein, human IL-10 protein, human IL-33 neutralizing antibody and human ST2 neutralizing antibody were from R&D Systems.

Techniques: Recombinant, Control

Journal: Calcified Tissue International

Article Title: Fibroblast Growth Factor 23 (FGF23) and Alpha-Klotho Stimulate Osteoblastic MC3T3.E1 Cell Proliferation and Inhibit Mineralization

doi: 10.1007/s00223-011-9501-5

Figure Lengend Snippet: FGFRs were expressed and modulated by FGF23 + Klotho, but not Klotho or FGF23 alone (B-DNA analysis). Cells were cultured in 12-well plates in differentiation medium (alpha-MEM/10% FBS/ascorbic acid [50 μg/mL]/BGP [10 mM]) and supplemented with huFGF23R176Q (F) (1 and 1,000 ng/mL), murine Klotho (KL) (50 ng/mL), their combination, or FGF2 (bFGF) for 14 days. a FGFR “IIIc” forms are preferentially expressed in MC3T3.E1 cells exposed to differentiation medium alone. b FGFR1(IIIc). c FGFR2(IIIc). d FGFR3(IIIc). Gene panel FGFR1(IIIb), FGFR1(IIIc), FGFR2(IIIb), FGFR2(IIIc), FGFR3(IIIc) and FGFR4. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01 compared with differentiation medium ( Diff. Medium )

Article Snippet: The p38 inhibitor SB203580 (PHZ1253, lot 72547179A, stock 50 mg/mL, 132 mM) was from Invitrogen; the phosphoinositide 3-kinase (P13 K) inhibitor LY294002 (9901, lot 9, stock 15.3 mg/mL, 50 mM) was from Cell Signaling (Hayward, CA); FGFR2(IIIc) neutralizing antibody (MAB716, lot FSQ02, stock 5 mg/mL, 33 μM (ND50 = 0.67–2.7 nM) and FGFR3 neutralizing antibody (MAB710, lot FTD02, stock 5 mg/mL, 33 μM (ND50 = 20–80 nM) were from R&D Systems.

Techniques: Cell Culture

Journal: Scientific Reports

Article Title: Stingray venom activates IL-33 producing cardiomyocytes, but not mast cell, to promote acute neutrophil-mediated injury

doi: 10.1038/s41598-017-08395-y

Figure Lengend Snippet: Signals derived from ST2 receptor mobilize leukocytes in post-capillary venules. Swiss mice ( n = 4–7 per group) were previously treated for 30 min with intraescrotal injection of 5 μg neutralizing anti-ST2 antibody, 100 μM peptide inhibitors of MyD88, 0.005 μM Wortamannin, 2 μM SP98059 or 0.05 μM SB203580. After that, animals were anesthetized and the cremaster muscle were exposed to topical application of 300 μg/ml of stingray venom or sterile saline in 30 µl. Mobilization of leukocytes in post-capillary venules ( A ) was observed for 30 min, and the number of rolling ( B ) and adherent ( C ) leukocytes were counted. The number of neutrophils ( D ) was counted in exudates of peritoneal cavities collected at 2 h from pretreated mice injected with ray venom. Results represent mean ± SEM. Results of two independent experiments are shown. * p < 0.05 compared with the control-group (dotted line) and # p < 0.05 compared to untreated mice that received topically applied ray venom.

Article Snippet: Thirty minutes before venom injection, different groups of mice were pretreated with a 500 μl i.p. injection containing 5 μg of neutralizing anti-mouse ST2 (ST2/IL-1R4, AF1004 - R&D Systems), 100 μM peptidyl MyD88 inhibitors (tlrl-pimyd - IMG-2005-1, Imgenex); 0.005 μM Wortamannin (Sigma, W1628); 2 μM PD98059 (Sigma) or 0.05 μM SB203580 (Sigma).

Techniques: Derivative Assay, Injection, Sterility, Saline, Control

Journal: Scientific Reports

Article Title: Stingray venom activates IL-33 producing cardiomyocytes, but not mast cell, to promote acute neutrophil-mediated injury

doi: 10.1038/s41598-017-08395-y

Figure Lengend Snippet: Neutrophilia induced by ray venom is modulated by innate molecules.

Article Snippet: Thirty minutes before venom injection, different groups of mice were pretreated with a 500 μl i.p. injection containing 5 μg of neutralizing anti-mouse ST2 (ST2/IL-1R4, AF1004 - R&D Systems), 100 μM peptidyl MyD88 inhibitors (tlrl-pimyd - IMG-2005-1, Imgenex); 0.005 μM Wortamannin (Sigma, W1628); 2 μM PD98059 (Sigma) or 0.05 μM SB203580 (Sigma).

Techniques: Injection, Negative Control

Journal: Scientific Reports

Article Title: Stingray venom activates IL-33 producing cardiomyocytes, but not mast cell, to promote acute neutrophil-mediated injury

doi: 10.1038/s41598-017-08395-y

Figure Lengend Snippet: Innate signals regulate the neutrophilia, IL-6 and TNF-α in stingray venom inflammation. Stingray venom (300 μg/ml) in 500 μl or sterile saline were injected i.p. into C57BL/6 WT or mast cell-deficient Kit Wsh/Wsh, ST2 −/− , and AHR −/− ; or in TLR2/4 −/− , MyD88 −/− and TRIF −/− ; or in NLRP3 −/− , ICE −/− and IL-1β −/− ; or in P2RX7 −/− and CD39 −/− ; or in IL-17A −/− and IL-17RA −/− , or in TBX21 −/− and IL-18R −/− . Two hours later, peritoneal cells were harvested and aliquots applied on glass slides were stained and neutrophils ( A ) were counted in a proportion of total cells. IL-6 ( B ) and TNF-α ( C ) were analyzed by CBA in the peritoneal exudates of C57BL/6 WT or deficient mice. Results represent mean ± SEM. Pooled results of two independent experiments are shown. * p < 0.05 compared with the control-group (dotted line) and # p < 0.05 compared to WT mice injected with ray venom.

Article Snippet: Thirty minutes before venom injection, different groups of mice were pretreated with a 500 μl i.p. injection containing 5 μg of neutralizing anti-mouse ST2 (ST2/IL-1R4, AF1004 - R&D Systems), 100 μM peptidyl MyD88 inhibitors (tlrl-pimyd - IMG-2005-1, Imgenex); 0.005 μM Wortamannin (Sigma, W1628); 2 μM PD98059 (Sigma) or 0.05 μM SB203580 (Sigma).

Techniques: Sterility, Saline, Injection, Staining, Control